PTPRC and prostate carcinoma: A study first identified functional fibroblast activation protein (FAP)-positive cCAFs in the peripheral blood of metastatic castration-resistant prostate cancer patients, classifying them into CD45+ and CD45− subpopulations based on CD45 expression.